REGN Becomes Final Major Drugmaker To Sign Trump’s Drug Pricing Pledge

{
  "signal_id": "2e54d18b-9eff-2f22-9123-00c09751f55c",
  "signal_type": "news",
  "signal_subtype": "invests_into_assets",
  "detected_at": "2026-10-17T11:17:01+00:00",
  "company": {
    "name": "Regeneron",
    "domain": "regeneron.com"
  },
  "data": {
    "url": "https://stocktwits.com/news-articles/markets/equity/regn-becomes-final-major-drugmaker-to-sign-trump-s-drug-pricing-pledge/cZBQQQSReT5",
    "title": "REGN Becomes Final Major Drugmaker To Sign Trump’s Drug Pricing Pledge - Stocktwits",
    "assets": "manufacturing and research-and-development infrastructure",
    "excerpt": "Regeneron will provide Otarmeni, its recently FDA-approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S.Regeneron will lower the Medicaid prices of its products to match those in other developed nations.REGN commits $9 billion in domestic R&D and manufacturing capacity.Regeneron Pharmaceuticals (REGN) on Thursday became the 17th and the final biopharma firm to sign Trump’s drug pricing agreement, which is a pledge to lower the cost of current and future life-altering medications. The deal commits Regeneron to lower prices on its current and future medicines for Medicaid patients to match the lowest rates paid in other developed nations. As part of the pact, the company will sell its blockbuster cholesterol drug Praluent for $225 - down from roughly $537 - through the TrumpRx.gov direct-to-consumer platform.\"For too long, American patients and taxpayers have shouldered a disproportionate share of the cost of biotechnology innovation - effectively subsidizing lower drug prices for other high-income nations that have not been paying their fair share,” said Dr. Schleifer, Board co-Chair, President and Chief Executive Officer of Regeneron. “Vilifying the biopharma industry has not produced lower prices for Americans, nor has it generated more innovation.” Regeneron is the last of the original 17 pharmaceutical companies that received letters from...",
    "summary": "Regeneron committed more than $9 billion to U.S.-based manufacturing and research-and-development infrastructure investments over the coming years.",
    "location": "United States",
    "planning": true,
    "image_url": "https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/large_regeneron_logo_resized_ff9d5819f7.jpg",
    "confidence": 0.9,
    "assets_tags": [
      "production",
      "research_and_development"
    ],
    "published_at": "2026-10-17T11:17:01Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "The company also committed more than $9 billion to U.S.-based manufacturing and research-and-development infrastructure investments over the coming years.",
    "amount_normalized": 9000000000
  }
}

curl https://signals.autobound.ai/v1/signals/2e54d18b-9eff-2f22-9123-00c09751f55c \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"regeneron.com","limit":20}'